For Healthcare Professionals Outside the US
Tafinlar + Mekinist is indicated for adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection; for first-line treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation; for adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Home > Efficacy > Adjuvant BRAF V600+ Melanoma > Quality of life
For the adjuvant treatment of Stage III BRAF V600 positive melanoma following complete resection

QOL matters for your patients—maintain it with TAFINLAR® (dabrafenib) + MEKINIST® (trametinib)1-3

Relapse has the largest impact on QOL

QOL matters for your patients --maintain it with TAFINLAR® (dabrafenib) + MEKINIST® (trametinib)
  • No significant difference was reported in VAS between patients who discontinued therapy early and those who did not2
  • At relapse, a more significant reduction in VAS was reported with placebo (-6.84, P<.001) than with TAFINLAR + MEKINIST (-6.02, P=.003)2,3
    • 106/166 patients relapsed with TAFINLAR + MEKINIST; 192/244 with placebo
  •  No decrease in patient QOL was observed in 12 months of treatment with TAFINLAR + MEKINIST2
border line

Make a significant impact on your patients’ risk of relapse without impacting their QOL.

border line

QOL, quality of life.

References: 1. Data on file. Novartis Pharmaceuticals Corp; 2018. 2. Schadendorf D, Hauschild A, Santinami M, et al. Effect on health-related quality of life of adjuvant treatment with dabrafenib plus trametinib in patients with resected stage III BRAF-mutant melanoma. Presented at the American Society for Clinical Oncology Annual Meeting; June 1-5, 2018; Chicago, IL. 3. Schadendorf D, Hauschild A, Santinami M, et al. Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF mutant melanoma. J Clin Oncol. 2018;36 (suppl; abstract 9590).

COVID-19 Update


Novartis is closely monitoring the evolving COVID-19 pandemic. For the most recent information on how Novartis is responding, visit the COVID-19 Information Center.

During this time of uncertainty it is important to communicate with your patients about COVID-19 to clarify that they should not stop their treatments except under the direction of the treating physician, and to ensure that patients have sufficient drug to avoid any treatment interruptions.

Reach out to your Novartis representative with any questions related to Novartis products.

04/20  G-ONC-1230566

COMBI-AD was a double-blind, placebo-controlled, Phase 3 trial that compared Tafinlar + Mekinist vs placebo4

ELIGIBILITY REQUIREMENTS

  • Resection of histologically confirmed Stage IIIA, B, or C with BRAF V600E or BRAF V600K mutation
  • ECOG performance status ≤1
  • No prior systemic anticancer treatment or radiotherapy for melanoma
TAFINLAR 150 mg BID + MEKINIST
2 mg QD (n=438)
imgh22

Placebo (n=432)

STUDY ENDPOINTS

  • Primary endpoint was RFS
  • Secondary endpoints were OS, distant metastasis-free survival, freedom from relapse, and safety
COMBI-d phase 3 study: Tafinlar® (dabrafenib) + Mekinist® (trametinib) vs Tafinlar® monotherapy